Trial Profile
The Comparative Study of Dipeptidyl Peptidase-IV Inhibitor [sitagliptin] and Sulfonylurea [glimepiride] on the Effect of Improving Glucose Variability and Oxidative Stress in Type 2 Diabetic Patients With Inadequate Glycemic Control on Metformin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 18 Jul 2013 Status changed from recruiting to completed, based on results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 30 Oct 2009 Planned end date changed from 1 Jun 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.